STOCK TITAN

HUTCHMED (HCM) CFO reports options and share stakes in Form 3

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

HUTCHMED (China) Ltd Chief Financial Officer Cheng Chig Fung filed an initial ownership report showing existing equity holdings, not new trades. He holds several share options over American depositary shares with exercise prices of $22.0900, $27.9400, $10.7500 and $12.5100, expiring between 2030 and 2033.

The filing also lists 1,463,698 ordinary shares and 56,693 American depositary shares held directly, plus 38,567 ordinary shares held indirectly through a Long Term Incentive Plan. Each American depositary share represents 5 ordinary shares, and plan awards are scheduled to vest in 2027 subject to vesting criteria.

Positive

  • None.

Negative

  • None.
SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Cheng Chig Fung

(Last) (First) (Middle)
C/O 48TH FLOOR, CHEUNG KONG CENTER,
2 QUEEN'S ROAD CENTRAL

(Street)
HONG KONG K3 00000

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
03/11/2026
3. Issuer Name and Ticker or Trading Symbol
HUTCHMED (China) Ltd [ HCM ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
ordinary shares 1,463,698 D
American depositary shares(1) 56,693 D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Share option (right to buy)(2) 04/28/2020 04/27/2030 American depositary shares 80,380 $22.09(3) D
Share option (right to buy)(2) 03/26/2021 03/25/2031 American depositary shares 48,100 $27.94(3) D
Share option (right to buy)(2) 05/23/2022 05/22/2032 American depositary shares 89,320 $10.75(3) D
Share option (right to buy)(2) 06/05/2023 06/04/2033 American depositary shares 12,340 $12.51(3) D
Long Term Incentive Plan awards granted on 08/05/2024 (4) (4) ordinary shares 38,567 (4) I Held by Long Term Incentive Plan trustee
Explanation of Responses:
1. Each American depositary share represents 5 ordinary shares.
2. The share options granted are exercisable subject to, amongst other relevant vesting criteria, the vesting schedule of 25% on each of the first, second, third and fourth anniversaries of the date of grant of share options.
3. The exercise price for the share option is denominated in United States dollar per American depositary share.
4. All Long Term Incentive Plan Awards will vest in 2027, three weeks after the date of completion of the share purchase for the awards for the financial year ending December 31, 2026.
/s/ Cheng Chig Fung 03/11/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does HUTCHMED (HCM) CFO Cheng Chig Fung report in this Form 3?

The Form 3 reports Cheng Chig Fung’s existing equity holdings in HUTCHMED, not new trades. It lists ordinary shares, American depositary shares, and multiple share option grants with specified exercise prices, expiration dates, and related Long Term Incentive Plan awards.

How many HUTCHMED (HCM) ordinary shares does the CFO hold directly?

The CFO is shown holding 1,463,698 ordinary shares directly. This is in addition to his American depositary shares and option grants, providing substantial direct equity exposure according to the ownership snapshot disclosed in the Form 3 filing.

What option awards over HUTCHMED (HCM) ADS does the Form 3 disclose?

The filing lists several share options over American depositary shares with exercise prices of $22.0900, $27.9400, $10.7500 and $12.5100, expiring between 2030 and 2033, giving the CFO long-dated incentives tied to ADS performance.

How are HUTCHMED (HCM) American depositary shares related to ordinary shares?

Each American depositary share represents 5 ordinary shares. This ratio, disclosed in the footnotes, helps investors translate the CFO’s ADS and ADS-linked option holdings into equivalent ordinary share exposure for a clearer picture of his total economic interest.

What Long Term Incentive Plan awards does the HUTCHMED (HCM) CFO hold?

The CFO has 38,567 ordinary shares held indirectly through a Long Term Incentive Plan. Footnotes state these awards are expected to vest in 2027, three weeks after completion of the share purchase for the financial year ending December 31, 2026.
Hutchmed (China) Limited

NASDAQ:HCM

View HCM Stock Overview

HCM Rankings

HCM Latest News

HCM Latest SEC Filings

HCM Stock Data

2.50B
174.47M
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
Hong Kong
CAMBRIDGE